PRO-XTEN™ protease-releasable masking technology

PRO-XTEN technology enables drug candidates to become active (or unmasked) only where they are needed, in the tumor microenvironment, mitigating damage off-tumor and reducing toxicity. It also helps drug candidates stay in the bloodstream longer in their inactive form, allowing them to better reach the site of action and potentially allowing more convenient dosing regimens for patients and clinicians. 

This masking approach could be key to pursuing validated oncology targets typically associated with therapies of high toxicity, ultimately offering an opportunity to increase efficacy and tolerability and deliver safer options for patients. 

We are currently investigating the PRO-XTEN technology in conjunction with T-cell engagers: potent anti-tumor agents that direct the immune system, specifically T-cells, to attack cancer cells. We are excited to explore the potential of this technology in a broad range of therapeutic modalities, with the goal of driving efficacy while reducing off-tumor toxicity. 

To learn more about diseases we are targeting using our masking technology, click here.